Please try another search
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Name | Age | Since | Title |
---|---|---|---|
Ron Cohen | 67 | 1995 | Founder, CEO, President & Director |
Sandra Panem | 76 | 1998 | Independent Director |
John P. Kelley | 69 | 2008 | Independent Non-Executive Chairman |
Michael S. Beattie | - | - | Member of Scientific Advisory Board |
Mark Tuszynski | - | - | Member of Scientific Advisory Board |
Melitta Schachner | - | - | Member of Scientific Advisory Board |
Carl W. Cotman | 83 | - | Member of Scientific Advisory Board |
Jerry Silver | - | - | Member of Scientific Advisory Board |
Jacqueline C. Bresnahan | - | - | Member of Scientific Advisory Board |
James W. Fawcett | - | - | Member of Scientific Advisory Board |
Eugene M. Johnson | - | - | Member of Scientific Advisory Board |
Mary B. Bunge | - | - | Member of Scientific Advisory Board |
Stephen G. Waxman | - | - | Member of Scientific Advisory Board |
Patrick A. Tresco | - | - | Member of Scientific Advisory Board |
Peder K. Jensen | 68 | 2011 | Independent Director |
John W. Varian | 63 | 2022 | Independent Director |
Thomas M. Burns | 49 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review